A protein known as SUPT6H: A Potential Drug Target and Biomarker

Target Name: SUPT6H

NCBI ID: G6830

SUPT6H

A protein known as SUPT6H: A Potential Drug Target and Biomarker

SUPT6H (tat-cotransactivator 2 protein) is a protein that has been identified as a potential drug target and biomarker. It is a non-coding RNA molecule that plays a critical role in the regulation of gene expression. The protein is expressed in various tissues and cells of the body and is involved in the regulation of various cellular processes.

During the past few years, researchers have been increasingly interested in identifying potential drug targets and biomarkers for various diseases. These targets can be used to develop new treatments and improve current treatments. The discovery of SUPT6H as a potential drug target and biomarker has significant implications for the development of new treatments for various diseases.

The ProteinSUPT6H

SUPT6H is a non-coding RNA molecule that is approximately 150 amino acids long. It is expressed in various tissues and cells of the body and is involved in the regulation of gene expression. The protein has been shown to play a critical role in the regulation of cellular processes, including cell growth, apoptosis, and inflammation.

One of the key functions of SUPT6H is its ability to activate the cotranscriptional regulation system. This system is responsible for the regulation of gene expression by ensuring that the necessary transcription factors are present in the cell at the time of gene expression.SUPT6H has been shown to play a critical role in the regulation of gene expression by ensuring that the necessary transcription factors are present in the cell at the time of gene expression.

In addition to its role in gene expression regulation, SUPT6H is also involved in the regulation of cellular processes such as cell growth, apoptosis, and inflammation. Studies have shown that the levels of SUPT6H are regulated by various factors, including cellular signaling pathways, and that its levels can be used as a biomarker for various diseases.

Potential Drug Target

SUPT6H has been identified as a potential drug target due to its involvement in the regulation of cellular processes that are associated with the development of various diseases. For example, SUPT6H has been shown to be involved in the regulation of cancer cell growth and has been used as a potential biomarker for cancer.

In addition to its involvement in cancer, SUPT6H is also involved in the regulation of autoimmune diseases. Studies have shown that SUPT6H is involved in the regulation of the immune response and has been used as a potential biomarker for autoimmune diseases.

Biomarker Potential

SUPT6H has also been identified as a potential biomarker for various diseases. Its involvement in the regulation of cellular processes that are associated with the development of these diseases makes it an attractive candidate as a biomarker.

For example, SUPT6H has been shown to be involved in the regulation of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have shown that the levels of SUPT6H are regulated by various factors, including cellular signaling pathways, and that its levels can be used as a biomarker for neurodegenerative diseases.

In addition to its potential as a biomarker for neurodegenerative diseases, SUPT6H has also been shown to be involved in the regulation of other diseases, including cardiovascular diseases and diseases of the respiratory system.

Conclusion

SUPT6H is a non-coding RNA molecule that is involved in the regulation of gene expression and has been identified as a potential drug target and biomarker for various diseases. Its involvement in the regulation of cellular processes that are associated with the development of these diseases makes it an attractive candidate as a potential drug target or biomarker. Further research is needed to

Protein Name: SPT6 Homolog, Histone Chaperone And Transcription Elongation Factor

Functions: Transcription elongation factor which binds histone H3 and plays a key role in the regulation of transcription elongation and mRNA processing. Enhances the transcription elongation by RNA polymerase II (RNAPII) and is also required for the efficient activation of transcriptional elongation by the HIV-1 nuclear transcriptional activator, Tat. Besides chaperoning histones in transcription, acts to transport and splice mRNA by forming a complex with IWS1 and the C-terminal domain (CTD) of the RNAPII subunit RPB1 (POLR2A). The SUPT6H:IWS1:CTD complex recruits mRNA export factors (ALYREF/THOC4, EXOSC10) as well as histone modifying enzymes (such as SETD2), to ensure proper mRNA splicing, efficient mRNA export and elongation-coupled H3K36 methylation, a signature chromatin mark of active transcription. SUPT6H via its association with SETD1A, regulates both class-switch recombination and somatic hypermutation through formation of H3K4me3 epigenetic marks on activation-induced cytidine deaminase (AICDA) target loci. Promotes the activation of the myogenic gene program by entailing erasure of the repressive H3K27me3 epigenetic mark through stabilization of the chromatin interaction of the H3K27 demethylase KDM6A

The "SUPT6H Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SUPT6H comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets